$94.3 Million is the total value of Foresite Capital Management III, LLC's 8 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics, Inc. | $34,328,000 | -30.3% | 1,954,904 | 0.0% | 36.39% | -15.9% | |
| NTRA | Natera, Inc. | $14,453,000 | +11.8% | 127,305 | 0.0% | 15.32% | +35.0% | |
| XLRN | Acceleron Pharma Inc. | $13,632,000 | -7.5% | 108,630 | 0.0% | 14.45% | +11.7% | |
| EPZM | Epizyme, Inc. | $8,296,000 | -4.6% | 998,278 | 0.0% | 8.79% | +15.2% | |
| FGEN | FibroGen, Inc. | $8,143,000 | -23.3% | 305,784 | 0.0% | 8.63% | -7.4% | |
| VRNA | Verona Pharma PLC.sponsored ads | $7,267,000 | -21.8% | 1,111,112 | 0.0% | 7.70% | -5.6% | |
| CBAY | Cymabay Therapeutics, Inc. | $7,158,000 | -4.0% | 1,641,804 | 0.0% | 7.59% | +15.9% | |
| NVAX | Novavax, Inc. | $1,062,000 | +17.1% | 5,000 | 0.0% | 1.13% | +41.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Epizyme, Inc. | 24 | Q3 2021 | 17.6% |
| Acceleron Pharma Inc. | 22 | Q3 2021 | 25.9% |
| CymaBay Therapeutics, Inc. | 20 | Q3 2022 | 17.6% |
| Aerie Pharmaceuticals, Inc. | 18 | Q1 2020 | 33.5% |
| Ascendis Pharma A/S | 17 | Q3 2022 | 47.8% |
| Alder BioPharmaceuticals, Inc. | 16 | Q3 2019 | 27.4% |
| Natera, Inc. | 16 | Q3 2022 | 21.5% |
| Aimmune Therapeutics, Inc. | 16 | Q3 2019 | 8.1% |
| Verona Pharma PLC. | 15 | Q3 2022 | 30.0% |
| WAVE Life Sciences Ltd. | 15 | Q2 2019 | 20.0% |
View Foresite Capital Management III, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
| 4 | 2021-11-03 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 3 | 2021-02-10 |
View Foresite Capital Management III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.